Onconic Therapeutics Inc. Logo

Onconic Therapeutics Inc.

Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.

476060 | KO

Overview

Corporate Details

ISIN(s):
KR7476060009
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로26길 12 제일비젼타워 11층, 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Onconic Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative drugs for cancer and gastrointestinal diseases. A subsidiary of Jeil Pharmaceutical, the company focuses on therapeutic areas with high unmet medical needs and significant market potential. Its development pipeline features novel treatments for acid-related conditions, including ZacuCorrection (zastaprazan), a next-generation potassium-competitive acid blocker (P-CAB) designed to treat gastroesophageal reflux disease. Onconic Therapeutics aims to advance its portfolio through clinical development and strategic collaborations to bring new therapeutic options to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주권매매거래정지 (무상증자)
Korean 4.8 KB
2025-09-17 00:00
Share Issue/Capital Change
주요사항보고서(무상증자결정)
Korean 10.2 KB
2025-09-15 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP1366)(자스타프라잔시트르산염)의 약물상호작용 확인을 위한…
Korean 11.6 KB
2025-09-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-01 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-19 00:00
Regulatory News Service
투자판단관련주요경영사항 (파트너사인 Livzon Pharmaceutical Group Inc.에 Zastaprazan(…
Korean 10.4 KB
2025-08-18 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인신청) (네수파립의 췌장암 제1b/2상 임상시험계획승인(변경승인)신청))
Korean 10.7 KB
2025-08-11 00:00
Interim Report
반기보고서 (2025.06)
Korean 929.6 KB
2025-08-01 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보정 JP-1366 약물상호작용 확인을 위한 1상 임상시험계획승인…
Korean 10.7 KB
2025-07-30 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인신청) (네수파립의 위암 제1b/w상 임상시험계획승인(변경승인)신청)
Korean 11.5 KB
2025-07-30 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (네수파립의 위암 제1b/2상 임상시험계획승인(변경승인)신청)
Korean 14.7 KB
2025-07-02 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP-1366)(자스타프라잔시트르산염)의 비미란성 위식도역류질환…
Korean 11.3 KB
2025-06-17 00:00
Regulatory News Service
투자판단관련주요경영사항 (국산신약 37호 자큐보정의 품목허가사항 변경허가 승인(위궤양 신규적응증 추가를 위한 한국 식품…
Korean 7.7 KB
2025-05-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Onconic Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Onconic Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Onconic Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.